January 17, 2025
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On Jan. 13, 2025, Grifols Therapeutics LLC withdrew one lot to the consumer level for Xembify® (immune globulin subcutaneous, human-klhw) 20% 4G vial due to an increased rate of reported hypersensitivity reactions with the affected lot. Xembify is an immune globulin solution indicated for treating primary humoral immunodeficiency (PI) in patients two years of age or older. Hypersensitivity and anaphylactic reactions are listed in the warning and precautions section for the prescribing information; however, this lot may pose a higher risk for these reactions. For prescribing details, see here.
Last updated: January 17, 2025